Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer

A Prospective Observational Trial of Xoft® Intraoperative Radiotherapy (IORT) as a Component of Breast Conserving Therapy (BCT) in Patients With Early-Stage Breast Cancer

Intraoperative radiotherapy (IORT) is a type of accelerated partial breast irradiation (APBI) in which radiation therapy is delivered to the breast tissue in a single treatment at the time of lumpectomy for breast cancer. The Xoft device (Axxent, Xoft, San Jose, CA) is a device that allows for IORT for breast cancer using kilovoltage (kV) photons. A central goal of this study is to report acute and late toxicities and cosmetic outcomes following breast IORT with the Xoft device in women with early-stage breast cancer treated with lumpectomy. The investigators hypothesize that IORT following lumpectomy will be safe and well tolerated with a lower rate of physician reported acute side effects than traditional whole breast radiation therapy after lumpectomy.

Study Overview

• Status: Terminated
• Conditions: Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage IIA; Breast Cancer, Invasive Ductal; Invasive Mammary Carcinoma
• Intervention / Treatment: Radiation: Intraoperative radiotherapy

Detailed Description

Details of Radiation Therapy: Both breast conserving surgery and IORT will be delivered as per standard practice. Lumpectomy and sentinel lymph node biopsy will be performed by the breast surgeon using standard techniques and as per standard of care. IORT with Xoft Axxent System will be given at the time of lumpectomy for early stage breast cancer. During the same operative procedure, a single fraction of radiation will be given to the lumpectomy bed with IORT. The Xoft Axxent treatment device size will be customized to the patient's anatomy based on the volume of lumpectomy cavity. The prescription dose will be 20 Gy prescribed to the surface of the lumpectomy cavity. Postoperative, external beam, whole breast radiation therapy will be given that the discretion of the treating physician based on the presence of high risk clinicopathologic features. Based on data from existing, published, clinical trials, it is estimated that 15% of patients will require postoperative radiation in addition to IORT. As with standard practice, all patients planned for IORT will be discussed pre- and post-surgery at the breast cancer multidisciplinary conference for pathology and radiology review.

Study outline: After patients complete lumpectomy and IORT, their acute and late toxicities and cosmetic outcome will be monitored on protocol. Patients will complete clinical follow up in radiation oncology at 4-6 weeks, 6 months, 1 year, 18 months, 2 years and then yearly for a total of 5 years. In accordance with standard clinical practice, patients will have toxicity assessment, physical exam, and cosmetic scoring by the physician. Physician toxicity assessment will be performed with Common Terminology Criteriae for Adverse Events (CTCAE) version 5.0, Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic (LENT-SOMA), and Radiation Therapy Oncology Group (RTOG) skin and toxicity scales. Physician cosmetic assessment will be performed with the Harvard Cosmetic Scale. Patients will also be asked to complete Breast Cancer Treatment Outcome Scale (BCTOS) self-assessment for patient reported cosmetic, functional and pain symptoms. Breast-Q version 2.0 will also be used to evaluate patient-reported cosmetic outcome, physical well being and adverse events.

A prospective database will be created and maintained. Patient data will be deidentified in the database with patients assigned unique study codes. Their assigned study code will be kept in a single encrypted file by the principal investigator.

This is an observational prospective study. To reduce selection bias, all eligible consecutive patients will be enrolled. The investigators expect the sample size to be around 20 per year with a total of 60 in three years. Multiple adverse radiation outcomes (including breast pain, radiation dermatitis, breast edema, seroma, infection) will be evaluated and compared with historical controls to detect if prevalence differs by 20% and 16% in two- and three-years accrual, respectively (n=40 in two years and n=60 in three years) at alpha=0.05 and power =80%.

Descriptive statistics (mean, median, standard deviation, minimum and maximum for continuous measures, and frequency and percentages for ordinal measures) related to participant characteristics, treatment and risk factors will be produced for the entire cohort and subsets of cohort. Differences in adverse radiation effects in the IORT protocol participants and historic controls will be assessed using the Cochran-Armitage test for trend or chi-squared test, as appropriate. Univariate analysis will be used to detect associations between cosmetic outcome and patient-specific and treatment-related factors by use of either a chi-squared test (categorical variables) or t-test (continuous variables). The freedom from ipsilateral breast tumor recurrence, progression free survival {PFS) and overall survival (OS) will be estimated by the Kaplan-Meier method. Differences in survival between the protocol cohort and historic controls will be evaluated through the estimated hazard rates using the unweighted log-rank tests. PFS and OS will be estimated along with 95% precise confidence intervals. In order to examine the significant factors, Cox proportional hazards regression models will be used in both uni-variable and multi-variable settings. Other factors to be analyzed are ethnicity, gender, age, and pathological subtype. The various factors will be placed into categorical variables. Simple logistic regression will be used to study association between a dichotomous outcome measure and any predictor. Once again, for any dichotomous outcome measure, the effect of other covariates (as listed above) will also be explored in addition to primary predictor using a multiple logistic regression analysis.

All results will be declared significant at significance level of 5%. Since there are multiple outcomes compared, the investigators will adjust significance level for multiple comparisons.

The investigators will maintain a prospectively collected database of patients who undergo treatment, the details of which are kept in their electronic medical record. This EMR is managed in the usual and customary manner throughout treatment and follow-up. An excel spreadsheet of patients' MRN and their assigned study code will be kept in a single encrypted file by the principal investigator. This encrypted file will remain on campus, secured in the principal investigator's office, and held under lock and key.

• Study Type: Observational
• Enrollment (Actual): 10

Contacts and Locations

Study Locations

• United States
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • James Graham Brown Cancer Center at the University of Louisville

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with invasive breast cancer that are clinically node negative, with tumors 2.5 cm or smaller in size.

Description

Inclusion Criteria:

• T1 or T2 invasive carcinoma of the breast undergoing breast conserving surgery
• Clinically lymph node negative and Memorial Sloan Kettering nomogram estimates 20% or less risk of positive sentinel node
• Tumors 2.5 cm or less in size (clinical preoperative staging)
• Estrogen receptor positive tumors (≥10%)
• Her2 negative/not over-expressed
• Patients 50 years of age or greater

Exclusion Criteria:

• Prior malignancy not in remission
• Active collagen vascular disease requiring active cytotoxic or immunotherapy
• Psychiatric or mental condition which would preclude informed consent
• Prior thoracic radiation which overlaps with IORT field
• Pregnant patients
• Patients <50 years
• Risk of positive sentinel lymph node >20% based on nomogram estimates
• Known lymph node metastases (i.e. clinically node positive)
• Patients with invasive lobular carcinoma
• Patients with pure DCIS
• Known multifocal or multicentric tumor
• Patients requiring neoadjuvant chemotherapy
• Patients requiring or choosing mastectomy with or without reconstruction
• Technical contraindications to IORT dose delivery including skin to balloon distance <7 mm
• Medical contraindication to IORT, radiation or breast conservation

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of patients with greater than or equal to grade 2 acute radiation toxicities	Adverse side effects of radiation grade 2 or higher as per CTCAE version 5.0	within 6 months of radiotherapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of patients with greater than or equal to grade 2 late radiation toxicities	Adverse side effects of radiation grade 2 or higher as per CTCAE version 5.0	starting three months after radiation and continuing for 5 years
Percentage of patients with good or excellent cosmetic outcome as assessed by the Harvard cosmesis scale	Breast cosmetic changes following IORT, assessed by the physician	starting immediately after radiation and continuing for 5 years
Percentage of patients who are very satisfied or somewhat satisfied by their cosmetic outcome as determined by the Breast-Q patient satisfaction self assessment	Patient assessed breast cosmetic changes following IORT	starting immediately after radiation and continuing for 5 years

Collaborators and Investigators

• Sponsor: University of Louisville

Study record dates

Study Major Dates

• Study Start (Actual): September 10, 2019
• Primary Completion (Actual): June 5, 2022
• Study Completion (Actual): June 5, 2022

Study Registration Dates

• First Submitted: September 10, 2019
• First Submitted That Met QC Criteria: September 11, 2019
• First Posted (Actual): September 12, 2019

Study Record Updates

• Last Update Posted (Actual): May 12, 2023
• Last Update Submitted That Met QC Criteria: May 10, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Breast Diseases; Neoplasms, Ductal, Lobular, and Medullary; Carcinoma, Ductal; Breast Neoplasms; Carcinoma, Ductal, Breast
• Other Study ID Numbers: 19-0448

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No